Core Viewpoint - The announcement highlights a significant licensing agreement between Jiangsu Xiansheng Zaiming Pharmaceutical Co., Ltd. and Ipsen Pharma SAS, granting Ipsen exclusive global rights to develop, manufacture, and commercialize the antibody-drug conjugate SIM0613 outside Greater China, with potential financial benefits for the company totaling up to $1.06 billion [1]. Group 1 - Jiangsu Xiansheng has entered into an exclusive licensing agreement with Ipsen Pharma for the ADC SIM0613, targeting LRRC15 [1]. - The agreement includes an upfront payment of $45 million, along with milestone payments related to research, regulatory, and commercialization achievements, and tiered royalties on sales [1]. - SIM0613 is designed to target LRRC15, which is highly expressed in various solid tumors and tumor-associated fibroblasts, while showing minimal expression in normal cells [1]. Group 2 - The ADC SIM0613 is engineered to penetrate tumors and tumor-associated fibroblasts effectively, demonstrating significant tumor regression in various preclinical in vivo models [1]. - The potential total financial inflow of $1.06 billion includes various payment structures, indicating a strong commercial opportunity for Jiangsu Xiansheng [1].
先声药业附属与Ipsen就SIM0613(LRRC15抗体偶联药物)签订独家授权许可协议